Journal profile · Neuroscience-Cognitive Neuroscience
Translational Neurodegeneration
ISSN 2047-9158 · BioMed Central · United Kingdom · Founded 2012
Translational Neurodegeneration: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 19.12; fully open access; APC about USD 3,090; median 162 days to acceptance (97 articles, last 24 months); 72 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Translational Neurodegeneration is published by BioMed Central and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Parkinson's Disease Mechanisms and Treatments, Alzheimer's disease research and treatments and Neurological disorders and treatments, together about 40.6% of its articles. Its main subfields are Neurology. (generated from OpenAlex topic counts and CAS ranking data)
Translational Neurodegeneration is an open access, peer-reviewed journal that covers research, therapeutics and education for all aspects of neurodegenerative diseases. By offering a high-visibility forum for new insights and discussions, Translational Neurodegeneration creates a novel interface between the fields of basic, translational, and clinical research. It includes Parkinson's disease and movement disorders, Alzheimer's disease and other dementias, motor neuron disease and other neurodegenerative diseases. Topics of interest include but are not limited to the following areas of neurodegenerative diseases: Epidemiology and pathogenesis Research into diagnosis and prevention Research into the disease pathogenesis Development of new drugs and cell therapy Drug delivery Rehabilitation Translational Neurodegeneration offers the opportunity for scientists, clinicians and physician-scientists to publish their research and clinical trials in a journal which is applicable to their specific field.
From the journal's Aims & Scope
Research area (LetPub): Neuroscience-Cognitive Neuroscience
Editor-in-chief Shengdi ChenPublisher website
Editorial board by country: 11 in mainland China (about 18%); most named United States 24, Mainland China 11, France 3, Italy 3, Australia 3 (61 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Parkinson's Disease Mechanisms and TreatmentsMedicine17%
- Alzheimer's disease research and treatmentsMedicine15.6%
- Neurological disorders and treatmentsMedicine8%
- Amyotrophic Lateral Sclerosis ResearchMedicine7%
- Neuroinflammation and Neurodegeneration MechanismsNeuroscience5.7%
- Dementia and Cognitive Impairment ResearchMedicine4.9%
- Genetic Neurodegenerative DiseasesNeuroscience4.4%
- Mitochondrial Function and PathologyBiochemistry, Genetics and Molecular Biology3.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Neurosciences | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Neurosciences | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Neurosciences | Zone 1 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASPublisher website
Other: Google Scholar, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 19.12LetPub ·
- Impact factor (publisher) 2025
- 19.1Publisher website ·
- 5-year impact factor (publisher) 2025
- 19.7Publisher website ·
- CiteScore 2026-06
- 25.9LetPub ·
- SJR 2026-06
- 4.99LetPub ·
- SNIP 2026-06
- 3.05LetPub ·
- h-index
- 28LetPub ·
- h-index
- 93OpenAlex ·
- i10-index
- 483OpenAlex ·
- 2-year mean citedness
- 17.33OpenAlex ·
- Self-citation rate
- 1.6%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 59LetPub ·
- Downloads per year (publisher) 2025
- 1,200,000Publisher website ·
Articles by year OpenAlex count · 635 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 50 | 50 | 63 |
| 2025 | 72 | 72 | 968 |
| 2024 | 68 | 68 | 2,261 |
| 2023 | 59 | 59 | 3,018 |
| 2022 | 58 | 58 | 4,257 |
| 2021 | 50 | 50 | 2,752 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
162 daysMedian, submission to acceptance · P25–P75 125 days – 204 days
- Acceptance to online
- median 32 days (97 articles)
- Submission to online
- median 199 days
- Sample
- 97 articles with submission and acceptance dates (140 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 10 weeksLetPub ·
- Submission to first decision
- 11 daysPublisher website ·
- Submission to publication (journal-reported)
- about 10 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 2,690 / USD 3,090 / GBP 2,290 | Yes | CC BY, CC0 | |
| OpenAlex | USD 2,990 / EUR 2,590 / GBP 2,190 | — | — | |
| LetPub | EUR 2,490 / USD 2,890 / GBP 2,090 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- BioMed Central
- Country or region
- United Kingdom
- Language
- English
- Founded
- 2012
- ISSN
- 2047-9158
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Translational Neurodegeneration
What CAS zone is Translational Neurodegeneration in?
In the 2025 upgraded edition of the CAS Journal Ranking, Translational Neurodegeneration is in Zone 1 of Medicine, and in Zone 1 of the minor category Neurosciences; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Translational Neurodegeneration?
The latest impact factor listed by LetPub is 19.12; CiteScore 25.9, h-index 93.
How long does peer review take at Translational Neurodegeneration?
Based on the dates recorded on 97 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 162 days (interquartile range 125–204 days); authors report an average review time of about 10 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Translational Neurodegeneration based?
Of the 61 board members whose country the journal's board page names, 11 (about 18%) are in mainland China; the countries named most often are United States (24), Mainland China (11) and France (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Translational Neurodegeneration?
According to LetPub and DOAJ records, Translational Neurodegeneration is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, Embase and CAS; that list has not been checked against each database.
Is Translational Neurodegeneration open access, and what is the APC?
Translational Neurodegeneration is a fully open-access journal. APC about USD 3,090.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .